ValenTx is a well-funded early-stage medical device company that has been developing a non-surgical, implantable medical therapy to treat morbid obesity and Type II Diabetes. The Company has successfully evaluated this treatment and has generated unsurpassed efficacy data in a series of human clinical trials, and is aggressively growing its Operations function in support of expanding the therapy’s utility.